おすすめの製品
製品名
CACO-2, Caucasian colon adenocarcinoma
由来生物
human colon
品質水準
フォーム
liquid
成長モード
(Adherent)
核型
(Hypertetraploid, modal no. 96)
形態
Epithelial
製品
Not specified
受容体
Not specified
テクニック
cell culture | mammalian: suitable
関連疾患
cancer
輸送温度
dry ice
保管温度
−196°C
細胞株の由来
Human caucasian colon adenocarcinoma, intestinal permeability characteristics tested
細胞株の説明
Isolated from a primary colonic tumour in a 72-year-old Caucasian male using the explant culture technique. Forms moderately well differentiated adenocarcinomas consistent with colonic primary grade II, in nude mice. This CACO-2 catalogue number has undergone testing for intestinal permeability: Dome, microvilli and tight junction formation and transport functionality tested and confirmed present at ECACC.
アプリケーション
CACO-2 has been used in the cytotoxicity studies with high pressure-assisted extraction (HPE) fraction of nettle leaf extracts.
CACO-2 may be used as a cell model to study:
CACO-2 may be used as a cell model to study:
- in vitro permeability assay with various biopharmaceuticals
- in iron uptake and absorption studies
- in the cytotoxicity assay with surfactants and transporter inhibitors
- in liposome formulated drug uptake and cytotoxicity studies
生物化学的/生理学的作用
Caco-2 (Cancer coli-2) is derived from colorectal adenocarcinoma and grows as an adherent monolayer of epithelial cells. Caco-2 cell line is a widely used intestinal epithelium model and has unique spontaneous differentiation and confluence property. It actively transports vitamins, hormones, amino acids and sugars. Caco-2 expresses various enzymes, ionic and non-ionic transporters similar to normal human epithelia. Caco-2 cell line models grow on filter support. They have simplicity and reproducibility and provide reliable information. Since Caco-2 mimics the intestinal epithelium, it is the preferred cell model for cytotoxic studies, food and drug transport studies.
DNAプロファイル
STR-PCR Data:
Amelogenin: X
CSF1PO: 11
D13S317: 11,13,14
D16S539: 12,13
D5S818: 12,13
D7S820: 11,12
THO1: 6
TPOX: 9,11
vWA: 16,18
Amelogenin: X
CSF1PO: 11
D13S317: 11,13,14
D16S539: 12,13
D5S818: 12,13
D7S820: 11,12
THO1: 6
TPOX: 9,11
vWA: 16,18
培地
EMEM (EBSS) + 2mM Glutamine + 1% Non Essential Amino Acids (NEAA) + 10% Foetal Bovine Serum FBS / FCS.
継代と培養方法
Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4x10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C. NB: During routine subculture the cells should always be subcultured before they achieve confluence. Cells may show the appearance of circular vacuoles in the cytoplasm. These may increase in frequency as the culture density increases to confluence. To reduce their frequency, media change confluent cultures after 2-3 days if not subcultured. Cells can clump if not separated into a single cell suspension when split.
その他情報
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
Cultures from HPA Culture Collections and supplied by Sigma are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.
NaviCyte Scientific holds the exclusive commercial distribution rights to the CACO-2 cell line deposited by the Memorial Sloan-Kettering Cancer Center. Note: All uses of Catalogue Numbers 86010202 and 09042001, other than for research by a non-commercial or academic entity, require a license and use authorization from NaviCyte Scientific under its exclusive arrangement with Memorial Sloan-Kettering Cancer Center. For information on the licensing terms, please contact NaviCyte Scientific via contact@navicyte-scientific.com or (+1) 973-868-6100.
免責事項
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
保管分類コード
10 - Combustible liquids
WGK
WGK 3
引火点(°F)
188.6 °F - closed cup
引火点(℃)
87 °C - closed cup
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
消防法
第4類:引火性液体
第三石油類
危険等級III
非水溶性液体
労働安全衛生法名称等を表示すべき危険物及び有害物
名称等を表示すべき危険物及び有害物
労働安全衛生法名称等を通知すべき危険物及び有害物
名称等を通知すべき危険物及び有害物
Jan Code
09042001-1VL:
09042001-VAR:
09042001-BULK:
9042001-1VL:
最新バージョンのいずれかを選択してください:
Frontiers in pharmacology, 7, 120-120 (2016-06-01)
Clostridium difficile infections (CDIs) caused by Clostridium difficile toxin A (TcdA) lead to severe ulceration, inflammation and bleeding of the colon, and are difficult to treat. The study aimed to evaluate the effect of rifaximin on TcdA-induced apoptosis in intestinal
Molecules (Basel, Switzerland), 20(11), 20269-20285 (2015-11-17)
Cyclodextrins, even the 6-membered α-cyclodextrin, are approved in the various pharmacopoeias as pharmaceutical excipients for solubilizing and stabilizing drugs as well as for controlling drug release. Recently α-cyclodextrin has also been marketed as health food with beneficial effects on blood
Phytomedicine : international journal of phytotherapy and phytopharmacology, 22(1), 36-44 (2015-02-01)
Extracts of saffron (Crocus sativus L.) have traditionally been used against depressions. Recent preclinical and clinical investigations have rationalized this traditional use. Trans-crocetin, a saffron metabolite originating from the crocin apocarotenoids, has been shown to exert strong NMDA receptor affinity
Biopharmaceutical classification of desloratadine-not all drugs are classified the easy way
Acta pharmaceutica (Zagreb, Croatia), 70, 131-144 (2020)
PloS one, 10(6), e0131363-e0131363 (2015-06-25)
Despite the demonstrated benefits of anti-EGFR/VEGF targeted therapies in metastatic colorectal cancer (mCRC), many patients initially respond, but then show evidence of disease progression. New therapeutic strategies are needed to make the action of available drugs more efficient. Our study
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)